Drugs Targeted Protein Degradation Treatment 
SugarCone Biotech
OCTOBER 6, 2024
Cancer cell viability was reduced by 50% - 80% after 7 days treatment in vitro, however only limited in vivo data was shown in this paper. Because Trf1 is degraded as part of the degradation of the internalized protein complex, these EGFR-bright cells become iron-starved and die as a consequence.
BMG Labtech
MAY 22, 2024
Options for cell-based protein degrader assays Interest is growing in the use of targeted-protein degradation to induce the breakdown of disease-causing proteins after treatment with small molecule drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Covalent Modifiers
FEBRUARY 1, 2024
Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers. Therefore, understanding mechanisms by which acquired mutations in BTK confer drug resistance and developing new therapies to overcome resistance are critically important.
Drug Target Review
JULY 5, 2024
1 Considerations for creating complex organoids Despite the numerous advantages of using brain organoids in drug discovery, some limitations should be considered. 1 Considerations for creating complex organoids Despite the numerous advantages of using brain organoids in drug discovery, some limitations should be considered.
The Pharma Data
DECEMBER 21, 2020
. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe. Captor’s Optigradeä platform is focused on improving the selectivity and performance of first-generation degrader drugs. TOKYO and CAMBRIDGE, England , Dec.
The Pharma Data
OCTOBER 15, 2020
a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.
The Pharma Data
JULY 22, 2021
NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Despite advancements in oncology in recent years, considerable unmet need persists in the treatment of HR+ breast cancer.
Expert insights. Personalized for you.
73 
Let's personalize your content